Product name: 7-Oxoganoderic acid Z
Synonym name:
Catalogue No.: BP2290
Cas No.: 929248-72-6
Formula: C₃₀H₄₆O₄
Mol Weight: 470.694
Botanical Source: Ganoderma
Type of Compound: Triterpenoids

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle

Storage: Store in a well closed container, protected from air and light. Put into refrigerate or freeze for long term storage.
Whenever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20℃. Generally, these will be useable for up to two weeks.

The product could be supplied from milligrams to grams
Inquire for bulk scale.

For Reference Standard and R&D, Not for Human Use Directly.

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

7-Carbonyl-Ganodermic acid Z (CAS No.: 929248-72-6) is a triterpene natural product derived from Ganoderma lucidum. As a traditional Chinese medicinal herb, Ganoderma lucidum has attracted attention due to its various biological activities, especially showing significant potential in anti-tumor, immunomodulatory, and anti-inflammatory properties. In recent years, with advances in natural product pharmacology and molecular biology technologies, 7-carbonyl-Ganoderchid acid Z has become a research hotspot in the field of cancer treatment due to its regulatory ability to target lung cancer-related molecules. This paper aims to systematically review the chemical structure and physicochemical properties of 7-carbonyl-Gathymic acid Z, its plant origin and extraction methods, pharmacological activity and mechanism, druggability evaluation and pharmacokinetic characteristics, and to explore its clinical application prospects and development directions.

Chemical structure and physicochemical properties

7-carbonyl-Ganoderium acid Z belongs to the Ganoderic acid triterpene compound, with a molecular formula of C_30H_46O_6 and a molecular weight of 470.6940. Its structural features include a multicyclic triterpene framework and carbonyl modifications, which give it unique biological activity. The compound has a LogP value of 5.7588, showing strong lipid solubility that facilitates penetration of cell membranes, but may limit its water solubility (solubility is only 0.0037 mg/mL), which poses challenges for its bioavailability. The topological pole surface area (TPSA) is 74.6 Ų, indicating that its molecules have moderate polarity, which helps bind to biological macromolecules. The blood-brain barrier has low permeability, suggesting it mainly acts on peripheral tissues and reduces the risk of central nervous system side effects. The hERG channel inhibition test was negative, indicating a low risk of cardiotoxicity. Ames mutagenicity test results were zero, indicating good genotoxicity safety.

Plant Origins and Extraction Methods

7-carbonyl-Ganoderma acid Z mainly originates from Ganoderma fungi, especially the fruiting bodies and mycelium of Ganoderma lucidum. Ganoderma is widely distributed in temperate and subtropical regions of Asia and has traditionally been used to boost immunity and treat anti-tumors. Common methods for extracting this compound include:

1. Solvent extraction: Organic solvents such as ethanol or methanol are used to reflux extract the dried Ganoderma lucidum powder. The extract is concentrated and then separated and purified.
2. Liquid-liquid partitioning: Using solvents of different polarities (such as ethyl acetate, n-hexane) to distribute the crude extract and enrich triterpene components.
3. Chromatographic separation: Purification of the extract using silica gel column chromatography, high-performance liquid chromatography (HPLC), and other technologies to obtain high-purity 7-carbonyl-Ganoderma acid Z.
4. Modern extraction technologies: Ultrasound-assisted extraction and microwave-assisted extraction methods improve extraction efficiency and purity, reducing solvent usage.

Optimizing extraction processes is of great significance for improving yield and purity, further promoting pharmacological research and industrial application.

Pharmacological activity research

The pharmacological activity of 7-carbonyl-Gachidermic acid Z is mainly concentrated in the anti-tumor field, especially its inhibitory effect on lung cancer cells. Multiple in vitro and in vivo studies have shown that this compound can significantly inhibit the proliferation, migration, and invasion of lung cancer cells, while also inducing apoptosis. Its antitumor activity involves regulation of multiple signaling pathways, specifically manifested as:

• Inhibits lung cancer cell proliferation: blocks the cell cycle process by interfering with cyclin expression.
• Induction of apoptosis: Activates mitochondrial pathways, regulates the expression of BCL2 family proteins, and promotes the activation of apoptosis-related proteins.
• Inhibition of tumor metastasis: Downregulates matrix metalloproteinase (MMPs) expression and suppresses tumor cell migration.
• Anti-inflammatory and immunomodulatory: By inhibiting PTGS2 (COX-2) expression, it reduces inflammatory responses in the tumor microenvironment and enhances the immune system's ability to recognize and clear tumors.

In addition, 7-carbonyl-Gathydermic acid Z also demonstrates certain protective effects in other disease models, such as antioxidant and antifibrotic effects, but related research is still in its early stages.

Mechanism of action and molecular targets

The molecular mechanism of 7-carbonyl-Gazhicid acid Z in lung cancer is complex, involving multiple key targets and signaling pathways:

• BCL2 family proteins: This compound can downregulate the expression of the anti-apoptotic protein BCL2, promote apoptosis, and restore the programmed death mechanisms of tumor cells.
• STAT3 signaling pathway: By inhibiting STAT3 phosphorylation and nuclear translocation, it blocks its transcriptional activity, reduces the expression of tumor-promoting genes, and inhibits tumor growth and immune escape.
• MAPK1 (ERK2) pathway: regulates cell proliferation and differentiation signals. 7-carbonyl-Gazhidated acid Z blocks tumor cell proliferation signaling by inhibiting MAPK1 activity.
• PI3K/Akt pathway: targets PIK3CG and PIK3CA subunits, inhibits PI3K activity, blocks downstream Akt signaling, promotes cell apoptosis, and suppresses tumor growth.
• EGFR receptor: Interferes with epidermal growth factor receptor (EGFR) signaling, inhibits its activation, and reduces tumor cell proliferation and survival.
• PTGS2 (COX-2): Inhibits the synthesis of inflammatory mediators, reduces tumor-related inflammation, and improves the tumor microenvironment.
• TP53 (p53 protein): Promotes the expression and activity of tumor suppressor gene TP53, enhancing cell cycle arrest and apoptosis.
• MAPT (microtubule-associated protein Tau) and KCNA5 (potassium channel): regulate cytoskeleton and ion channel function, affecting tumor cell migration and invasion capabilities.

The synergistic regulation of these targets gives 7-carbonyl-Ganodermic acid Z multi-target and multi-pathway antitumor properties, laying a solid foundation for its role as a candidate drug for lung cancer treatment.

Druggability evaluation and pharmacokinetics

From the perspective of druggability, 7-carbonyl-Gazhid acid Z exhibits the following characteristics:

• It has high lipid solubility (LogP=5.7588), which facilitates cell membrane penetration, but may cause poor water solubility, affecting oral absorption and bioavailability.
• Its extremely low water solubility (0.0037 mg/mL) limits drug formulation design, requiring improved solubility through technologies such as nanocarriers, liposomes, or solid dispersions.
• The blood-brain barrier has low permeability, reducing the risk of central nervous system toxicity, but its application in brain tumor treatment is limited.
• hERG channel inhibition is negative, indicating a low risk of cardiotoxicity and good safety.
• No mutagenicity (Ames test negative), with relatively high genotoxicity safety.

Currently, pharmacokinetic data on 7-carbonyl-Gazhidated acid Z are relatively limited. Current research indicates that metabolism in the body mainly occurs through hepatic enzyme systems, and the metabolites have not yet been systematically identified. After oral administration, due to poor water solubility, low bioavailability, plasma half-life and volume of distribution require further study. Systematic pharmacokinetic and toxicological evaluations are needed in the future to provide a basis for clinical development.

Prospects and outlooks for clinical applications

Given the significant regulatory effect and favorable safety profile of 7-carbonyl-Ganodermic acid Z on multiple targets related to lung cancer, it has great potential as a candidate for new drugs against lung cancer. Future clinical application focuses include:

1. Lung cancer treatment: combining chemotherapy, targeted therapy, or immunotherapy to achieve synergistic effects and overcome resistance to single treatments.
2. Drug formulation optimization: Develop new drug delivery systems, such as nanocarriers, liposomes, and solid dispersions, to improve water solubility and bioavailability.
3. Combination therapy strategy: Exploring the safety and efficacy of combining with existing lung cancer drugs (such as EGFR inhibitors and PD-1/PD-L1 antibodies).
4. Multi-target disease therapy: Given its regulation of multiple signaling pathways, it may be expanded in the future to treat other tumor types and inflammation-related diseases.
5. Preclinical and clinical research: Strengthen pharmacokinetics, toxicology, and pharmacodynamic studies, promote clinical trials, and verify their efficacy and safety.

In addition, pharmacological research on Ganoderma lucidum and its active ingredients still requires in-depth research. As a representative triterpene compound, 7-carbonyl-Gaetheric acid Z offers broad opportunities for new drug development through structural modification and derivative development.

Conclusion

7-carbonyl-Ganoderma acid Z, as an important triterpene active component in Ganoderma lucidum, demonstrates excellent pharmacological activity and safety due to its unique chemical structure and multi-target anti-lung cancer mechanism. Although there are certain limitations in water solubility and bioavailability, improvements in modern drug formulation technology are expected to overcome these bottlenecks and achieve clinical translation. In the future, combined with systematic pharmacokinetic studies and clinical trial validation, 7-carbonyl-Ganodermic acid Z is expected to become a novel natural drug for treating lung cancer and related diseases, contributing significantly to the development of natural product pharmacology.